Questcor Presenting Attractive Entry Point For Investors

Questcor Pharmaceuticals

is believed by Oppenheimer that its Medicaid reserve for rebates is adequate to cover requests from the states, including managed care Medicaid. Recent weakness in QCOR shares is attributed to the departure of its CMO and is presenting an attractive entry point for investors, according to Oppenheimer. Oppenheimer maintains its Buy rating and $14 price target. Questcor Pharmaceuticals closed yesterday at $9.84.